A Phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/ primitive neuroectodermal tumor, or brainstem glioma: A children's oncology group study

Cancer

Volumn 110, Issue 11, 2007, Pages 2535-2541

  Fouladi, Maryam ^a   Nicholson, H Stacy ^b   Zhou, Tianni ^c   Laningham, Fred ^a   Helton, Kathleen J ^a   Holmes, Emi ^c   Cohen, Kenneth ^d   Speights, Rose Anne ^a   Wright, John ^e   Pollack, Ian F ^f  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Farnesyl transferase inhibitor; Phase II trial; Recurrent central nervous system malignancies; Tipifarnib

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; ASTHENIA; BRAIN STEM TUMOR; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GLIOMA; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERMAGNESEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; LETHARGY; LEUKOPENIA; LIFE EXPECTANCY; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDULLOBLASTOMA; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROECTODERM TUMOR; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SEIZURE; SIDE EFFECT; SKIN ULCER; SURVIVAL RATE; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; MALE; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS; QUINOLONES; TREATMENT OUTCOME;

EID: 36448939729     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23078     Document Type: Article

References (53)

1. Bouffet E, Doz F, Demaille MC, et al. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse? Br J Cancer. 1998;77:1321-1326.
2. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol. 1996;14:1922-1927.
3. Crafts DC, Levin VA, Edwards MS, Pischer TL, Wilson CB. Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. J Neurosurg. 1978;49:589-592.
4. Lefkowitz IB, Packer RJ, Sutton LN, et al. Results of the treatment of children with recurrent gliomas with lomustine and vincristine. Cancer. 1988;61:896-902.
5. Wara WM, Le QT, Sneed PK, et al. Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy. Int J Radiat Oncol Biol Phys. 1994;30:551-556.
6. Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol. 1998;16:222-228.
7. Bredel M, Pollack IF. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Brain Res Brain Res Rev. 1999;29:232-249.
8. Gerosa MA, Talarico D, Fognani C, et al. Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J Natl Cancer Inst. 1989;81:63-67.
9. Gutmann DH, Giordano MJ, Mahadeo DK, Lau N, Silbergeld D, Guha A. Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras. Oncogene. 1996;12:2121-2127.
10. Pollack IF, Bredel M, Erff M. Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors. Pediatr Neurosurg. 1998;29:228-244.
11. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001;29:143-152.
12. Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery. 1998;43:124-131.
13. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyl-transferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
14. Prendergast GC. Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer. 2001;1:162-168.
15. Prendergast GC, Davide JP, deSolms SJ, et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 1994;14:4193-4202.
16. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 1995;55:5302-5309.
17. Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 1990;4:3319-3328.
18. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 1999;19:1831-1840.
19. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 1998;17:1439-1445.
20. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000;20:139-148.
21. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275:30451-30457.
22. Glass TL, Liu TJ, Yung WK. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro-oncology. 2000;2:151-158.
23. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 1999;18:7514-7526.
24. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
25. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18:927-941.
26. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
27. Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2002;20:2726-2735.
28. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004;103:3271-3277.
29. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007;109:4158-4163.
30. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109:1387-1394.
31. Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003;21:1301-1306.
32. Rosenberg JE, von der Maase H, Seigne JD, et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 2005;103:2035-2041.
33. Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol. 2004;15:1187-1193.
34. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:1760-1766.
35. Rao S, Cunningham D, de Gramont A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol. 2004;22:3950-3957.
36. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
37. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of 2 dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003;21:2492-2499.
38. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium study. J Clin Oncol. 2006;24:3651-3656.
39. Widemann BC, Saltzer RJ, Arceci RJ, et al. Phase I trial of R115777, an oral farnesyltransferase inhibitor, in children with refractory solid tumor and neurofibromatosis. J Clin Oncol. 2006;24:507-516.
40. Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
41. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the 8-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol. 1995;13:112-123.
42. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81:690-698.
43. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J Clin Oncol. 1999;17:2127-2136.
44. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202-4208.
45. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813-820.
46. Rood BR, MacDonald TJ. Pediatric high grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neuro-oncol. 2005;75:267-272.
47. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology. 1999;1:44-51.
48. Di Sapio A, Morra I, Pradotto L, Guido M, Schiffer D, Mauro A. Molecular genetic changes in a series of neuroepithelial tumors of childhood. J Neuro-oncol. 2002;59:117-122.
49. Raffel C, Fredrick L, O'Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival in patients with PTEN mutations. Clin Cancer Res. 1999;5:4085-4090.
50. Bredel M, Pollack IF, Hamilton RL, James CD. Epidermal growth factor receptor expression and gene amplification in high grade non-brainstem gliomas of childhood. Clin Cancer Res. 2000;5:1786-1792.
51. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol. 2000;10:249-259.
52. Siegel-Lakhai WS, Crul M, De PP, et al. Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. J Clin Oncol. 2006;24:4558-4564.
53. Jones HA, Hahn SM, Bernhard E, McKenna WG. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001;11:328-337.